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ABSTRACT
Relapsed osteosarcoma is a recalcitrant tumor. A patient’s cisplatinum (CDDP)-
resistant relapsed osteosarcoma lung metastasis was previously established 
orthotopically in the distal femur of mice to establish a patient-derived orthotopic 
xenograft (PDOX) model. In the present study, the PDOX models were randomized 
into the following groups when tumor volume reached 100 mm3: G1, control without 
treatment; G2, CDDP (6 mg/kg, intraperitoneal (i.p.) injection, weekly, for 2 weeks); 
gemcitabine (GEM) (100 mg/kg, i.p., weekly, for 2 weeks) combined with docetaxel 
(DOC) (20 mg/kg, i.p., once); temozolomide (TEM) (25 mg/kg, p.o., daily, for 2 
weeks) combined with irinotecan (IRN) (4 mg/kg i.p., daily for 2 weeks). Tumor 
size and body weight were measured with calipers and a digital balance twice a 
week. After 2 weeks, all treatments significantly inhibited tumor growth except CDDP 
compared to the untreated control: CDDP: p = 0.093; GEM+DOC: p = 0.0002, TEM+IRN:  
p < 0.0001. TEM combined with IRN was significantly more effective than either CDDP 
(p = 0.0001) or GEM combined with DOC (p = 0.0003) and significantly regressed 
the tumor volume compared to day 0 (p = 0.003). Thus the PDOX model precisely 
identified the combination of TEM-IRN that could regress the CDDP-resistant relapsed 
metastatic osteosarcoma PDOX.
INTRODUCTION
Osteosarcoma is a recalcitrant tumor with greatest 
is incidence in adolescence and in the seventh and eighth 
decades. First-line therapy for osteosarcoma is high-dose 
methotrexate (MTX), cisplatinum (CDDP), doxorubicin 
(DOX), and ifosfamide, which is ineffective in metastatic 
osteosarcoma with less than 20% long-term survival and 
has not improved for many years [1–8]. 
Temozolomide (TEM) has been tested pre-
clinically against osteosarcoma cells combined with 
a molecular targeting drug [9] and as a single-agent 
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against osteosarcoma xenograft models [10] as well 
as in combination with irinotecan (IRN) in a patient-
derived orthotopic xenograft (PDOX) model or 
rhabdomysarcoma [11].
Trabectedin (TRAB) is an alkylating agent derived from 
the Caribbean tunicate, Ecteinascidia turbinate [11] which has 
been tested on liposarcoma and leiomyosarcoma patients [12, 
13], TRAB arrests cells in the G2/M phase of the cell cycle 
[14], TRAB has shown efficacy against CDDP-resistant bone 
cancer in vitro [15]. TRAB is marketed as Yondelis (Johnson 
& Johnson, Raritan, NJ) for leiomyosarcoma and liposarcoma 
[16]. TRAB has been used for recurrent osteosarcoma patients 
with a 12% partial response rate [17]. 
The combination of gemcitabine (GEM) and 
docetaxel (DOC) may be synergistic due to their 
complementary mechanisms of action of arresting cells in 
different phases of the cell cycle [19].
We previously reported that a subcutaneous transplant 
nude-mouse model of a CDDP-resistant ostoeosarcoma lung 
metastasis was regressed by tumor-targeting Salmonella 
typhimurium A1-R (S. typhimurium A1-R), but was only 
partially sensitive to the molecular-targeting drug sorafenib, 
which did not arrest its growth. S. typhimurium A1-R was 
significantly more effective than sorafenib [18]. 
Toward the goal of individualized precision 
oncology, our laboratory pioneered the PDOX nude 
mouse model with the technique of surgical orthotopic 
implantation (SOI), including pancreatic [19–22], 
breast [23], ovarian [24], lung [25], cervical [26], colon 
[27–29], and stomach cancer [30], sarcoma [31–35] and 
melanoma [36–38]. 
We subsequently developed a PDOX model from the 
CDDP-resistant osteosarcoma lung metastasis that recurred 
after adjuvant CDDP treatment of the patient [8]. The CDDP-
resistant metastatic osteosarcoma PDOX was sensitive to 
TEM and TRAB, but not CDDP. These results showed that 
the PDOX model of the CDDP-resistant osteosarcoma lung-
metastasis could identify potentially, highly-effective drugs 
for this recalcitrant disease, while accurately maintaining the 
CDDP resistance of the tumor in the patient [8].
In the present study, we evaluated the efficacy TEM 
combined with IRT, compared to GEM combined with 
DOC compared to CDDP on the PDOX model of CDDP-
resistant relapsed osteosarcoma.
RESULTS AND DISCUSSION
Efficacy of CDDP alone, GEM combined with 
DOC and TEM combined with IRN on the CDDP-
resistant metastatic osteosarcoma PDOX mouse 
model
After 2 weeks, all treatments, except CDDP, 
significantly inhibited tumor growth compared to 
untreated control: CDDP: p = 0.093; GEM+DOC: 
p = 0.0002, TEM+IRN: p < 0.0001. TEM combined with 
IRN was significantly more effective than either CDDP 
(p = 0.0001) or GEM combined with DOC (p = 0.0003) 
and significantly regressed the tumor volume compare to 
day 0 (p = 0.003) (Figures 1–3).
The CDDP-resistant metastatic osteosarcoma 
PDOX faithfully replicated the CDDP-resistance of 
the tumor in the patient. The PDOX model could also 
identify the TEM-IRN combination which could regress 
the tumor indicating potential for efficacy in the patient 
[39]. The utility of the PDOX model is to match the drug 
to the patient. The TEM+IRN combination appears most 
promising as TEM alone did not regress the tumor [8].
Effect of treatment on the body weight of PDOX models
The body weight of treated mice was not 
significantly different in any group (Figure 4). There were 
no animal deaths in any group.
Effect of treatment on the histology of PDOX models
High power microscopy of the original patient tumor 
demonstrated neoplastic chondroid matrix occupied by 
anaplastic cells [8]. The tumor had hypercellular areas 
populated by anaplastic cells displaying nuclear pleomorphism, 
coarse and hyperchromatic chromatin and abundant mitotic 
figures (Figure 5A). High-power microscopy of the untreated 
PDOX tumor showed a solid and chondroblastic appearance 
similar to the patient's original tumor. Hypercellular areas 
were filled with cancer cells displaying nuclear pleomorphism 
and mitotic figures (Figure 5B) [8]. The PDOX tumor treated 
with CDDP comprised viable cells without apparent necrosis 
or inflammatory changes similar to the untreated control 
(Figure 5C). PDOX tumors treated with GEM+DOC showed 
changes in cancer-cell shape with slight areas of necrosis 
(Figure 5D). The TEM+IRN treated tumor showed more 
extensive tumor necrosis which is consistent with tumor 
regression after this treatment (Figure 5E). 
In the largest soft-tissue sarcoma (STS) PDOX study 
to date, we previously demonstrated a 62% establishment 
rate among untreated high-grade sarcoma with a median 
establishment time of 54 days [40]. These results demonstrated 
that the PDOX model is a practical model for precision 
oncology for sarcoma patients. 
The present results are a good example of precisely 
identifying a drug, the combination of TEM+ IRN that has 
potential for efficacy in the patient with CDDP-resistant lung 
metastatic osteosarcoma. 
This result demonstrated the broad potential utility 
of the PDOX model for sarcoma and likely for other 
diseases as well with the goal of matching the patient with 
an effective drug or combination. 
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [41–46]. 
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MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
Animals were housed in a barrier facility on a high 
efficiency particulate arrestance (HEPA)-filtered rack 
under standard conditions of 12-hour light/dark cycles. 
The animals were fed an autoclaved laboratory rodent diet. 
All animal studies were conducted with an AntiCancer 
Institutional Animal Care and Use Committee (IACUC)-
protocol specifically approved for this study and in 
accordance with the principles and procedures outlined in 
the National Institute of Health Guide for the Care and Use 
of Animals under Assurance Number A3873-1. In order 
to minimize any suffering of the animals, anesthesia and 
analgesics were used for all surgical experiments. Animals 
were anesthetized by subcutaneous injection of a 0.02 ml 
solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, 
and 0.48 mg/kg acepromazine maleate. The response of 
animals during surgery was monitored to ensure adequate 
depth of anesthesia. The animals were observed on a daily 
basis and humanely sacrificed by CO2 inhalation when 
they met the following humane endpoint criteria: severe 
tumor burden (more than 20 mm in diameter), prostration, 
significant body weight loss, difficulty breathing, 
rotational motion and body temperature drop [8]. 
Patient-derived tumor
The study was previously reviewed and approved by 
the UCLA Institutional Review Board (IRB #10-001857). 
Written informed consent was previously obtained 
from the patient as part of the above-mentioned UCLA 
Institutional Review Board-approved protocol [8]. A 16-
year old patient with localized left-distal-femoral high-
grade osteosarcoma underwent CDDP-based neoadjuvant 
chemotherapy and limb-salvage distal-femoral 
replacement. The tumor necrosis extent of the primary 
tumor after CDDP based chemotherapy was 70%. One 
year later, the osteosarcoma relapsed with three bilateral 
metachronous pulmonary metastases. The patient was 
treated with curative surgery at the Division of Surgical 
Oncology, University of California, Los Angeles (UCLA). 
The patient did not receive neoadjuvant chemotherapy or 
radiotherapy prior to lung surgery [8].
Surgical orthotopic implantation (SOI) for 
establishment of the PDOX osteosarcoma model
A lung metastasis from the osteosarcoma patient 
was previously established subcutaneously in mice [18]. 
Subcutaneously-grown tumors were harvested and cut 
into small fragments (3–4 mm). After nude mice were 
anesthetized, a 10 mm skin incision was made on the 
right thigh, the vastus lateralis muscle was opened and 
Figure 1: Treatment schema.
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Figure 2: Quantitative efficacy of treatment. Tumor volume was measured at the indicated time points after the onset of treatment. 
Please see the Materials and Methods for details. N = 8 mice/group. *p < 0.001
Figure 3: Photographs of treated and untreated tumors. Photos of representative treated and untreated osteosarcoma PDOX 
models.
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Figure 4: Effect of treatments on mouse body weight. Bar graph shows body weight in each group at pre-treatment and 2 weeks 
after drug administration. There were no significant differences between each group.
Figure 5: Effect of treatments on PDOX tumor histology. Hematoxylin and eosin (H&E)-stained section of the (A) original 
patient tumor; (B) untreated PDOX tumor; (C) PDOX tumor treated with CDDP; (D) PDOX tumor treated with GEM+DOC; (E) PDOX 
tumor treated with TEM+IRN. Scale bars: 80 µm.
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the biceps femoris muscle was split to reach the distal 
femur. An incision was made in the lateral patello-femoral 
ligament, sparing the knee joint and then the lateral 
condyle of the femur was resected. A single 3 to 4 mm 
tumor fragment was implanted orthotopically into the 
space to establish a PDOX model. The muscle and wound 
was closed with 6-0 nylon suture (Ethilon, Ethicon, Inc., 
NJ, USA) [8, 18].
Treatment study design
The PDOX models were randomized into the 
following groups when tumor volume reached 100 mm3: 
G1, control without treatment; G2, CDDP (6 mg/kg, 
intraperitoneal (i.p.) injection, weekly, for 2 weeks); G3, 
GEM (100 mg/kg, i.p., weekly, for 2 weeks) combined 
with DOC (20 mg/kg, i.p., once); G4, TEM (25 mg/kg, 
p.o., daily, for 2 weeks) combined with IRN (4 mg/kg 
i.p., daily for 2 weeks) (Figure 1). Tumor sizes and body 
weight were measured with calipers and digital balance 
twice a week.
Histological analysis
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (3 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocol. Histological examination was performed with 
a BHS system microscope. Images were acquired with 
INFINITY ANALYZE software (Lumenera Corporation, 
Ottawa, Canada) [8].
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